SCHEMBL482867

SCHEMBL482867

C=CCOC(=O)c1[c]cccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.59
ALDH1A1 P00352 5/20 0.51
HSD17B10 Q99714 3/20 0.51
TSHR P16473 2/20 0.51
RHOA P61586 1/20 0.44
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
PKM P14618 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SNCA P37840 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
POLB P06746 1/20 0.37
APP P05067 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11336915 0.81 TDP1 (0.35) CYP3A4ALDH1A1HSD17B10TSHRKMT2A
SCHEMBL7626169 0.80 CYP3A4 (0.42) CYP3A4ALDH1A1HSD17B10TSHRRHOA
SCHEMBL9421001 0.80 THRB (0.53) CYP3A4ALDH1A1HSD17B10TSHRMAPK1
SCHEMBL3716825 0.79 TDP1 (0.36) CYP3A4ALDH1A1TSHRKMT2ALMNA
SCHEMBL129333 0.77 TSHR (0.55) CYP3A4ALDH1A1HSD17B10TSHRNPSR1
SCHEMBL2443804 0.76 TDP1 (0.59) CYP3A4ALDH1A1TSHRKMT2AMAPT
SCHEMBL8673620 0.76 TSHR (0.53) CYP3A4ALDH1A1HSD17B10TSHRNPSR1
SCHEMBL11414429 0.75 KDM4E (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL130905 0.75 ALDH1A1 (0.58) CYP3A4ALDH1A1HSD17B10TSHRMEN1
SCHEMBL16371573 0.74 CYP3A4 (1.00) CYP3A4ALDH1A1HSD17B10TSHRRHOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099156-A1 Heterocyclic Compounds as Ccr2b antagonists ASTRAZENECA AB (SE) 2009-04-16 US claimed
CN-100344613-C Preparatino method of (2S,4S)-1-(4-nitro carbobenzoyl)-2-[(3-allyloxycarbonyl)-phenyl aminoformyl]-pyrrolidine -4-thioalcohol UNIV SHANGHAI JIAOTONG (CN) 2007-10-24 CN claimed
EP-1831164-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS AstraZeneca AB (SE) 2007-09-12 EP claimed
US-20060211626-A1 For treating preterm labor and dysmenorrhea THERATECHNOLOGIES, INC. (CA) 2006-09-21 US claimed
WO-2006067401-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS ASTRAZENECA AB (SE) 2006-06-29 WO claimed
CN-1752073-A Preparatino method of (2S,4S)-1-(4-nitro carbobenzoyl)-2-[(3-allyloxycarbonyl)-phenyl aminoformyl]-pyrrolidine -4-thioalcohol UNIV SHANGHAI JIAOTONG (CN) 2006-03-29 CN claimed
EP-1511764-A2 PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F sb 2a /sb RECEPTOR THERATECHNOLOGIES INC. (CA) 2005-03-09 EP claimed
EP-0879231-B1 DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS UNIV VANDERBILT (US) 2004-09-22 EP claimed
WO-2003104266-A2 PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F2α RECEPTOR THERATECHNOLOGIES INC. (CA) 2003-12-18 WO claimed
US-6262098-B1 ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-07-17 US claimed
WO-2023214017-A1 CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER VIROVET NV (BE) 2023-11-09 WO disclosed
CN-110446739-B Fluoroacetophenone-containing derivative, fluorine-containing additive, curable composition containing the same, and cured product thereof DIC株式会社 2022-01-11 CN disclosed
US-10961405-B2 Fluorine-containing acetophenone derivative, fluroine based additive, curable composition including same, and cured product thereof DIC CORPORATION (JP) 2021-03-30 US disclosed
US-10852236-B2 Method of measuring plant nutrient transport using near-infrared imaging Curadel, LLC (US) 2020-12-01 US disclosed
CN-111954849-A Photosensitive resin composition, cured product, insulating material, resin material for solder resist, and resist member DIC株式会社 2020-11-17 CN disclosed
WO-1996007651-A1 DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY (US) 1996-03-14 WO disclosed
WO-1996003396-A1 DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY (US) 1996-02-08 WO disclosed
US-4845094-A HYPOGLYCEMIC, ANTICOAGULANT SUNTORY LIMITED (JP) 1989-07-04 US disclosed
US-4720500-A N-1,8-naphthyridin-2-yl amides useful as immunostimulants RHONE-POULENC SANTE (FR) 1988-01-19 US disclosed
EP-0250265-A1 2-Phenylbenzoxepin derivative SUNTORY LIMITED (JP) 1987-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211626-A1 For treating preterm labor and dysmenorrhea PGF, PTGFR, PTGER1 CYP3A4 2390/4885ALDH1A1 2607/4885HSD17B10 1635/4885
US-20090099156-A1 Heterocyclic Compounds as Ccr2b antagonists CCR2, CCR3, CXCR2 CYP3A4 1686/4885ALDH1A1 3415/4885HSD17B10 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.